Stefano Cianfarani1, Elena Inzaghi2, Anna Alisi3, Daniela Germani4, Antonella Puglianiello4, Valerio Nobili3. 1. Department of Pediatrics, University Hospital, Bambino Gesù Children's Hospital, Tor Vergata University, Rome, Italy; Department of Women's and Children's Health, Karolinska Institute, Stockholm, Sweden. Electronic address: stefano.cianfarani@opbg.net. 2. Department of Pediatrics, University Hospital, Bambino Gesù Children's Hospital, Tor Vergata University, Rome, Italy. 3. Hepatometabolic Disease Unit, Bambino Gesù Children's Hospital, Rome, Italy. 4. Department of Systems Medicine, Tor Vergata University, Rome, Italy.
Abstract
OBJECTIVE: To correlate circulating levels of insulin-like growth factor (IGF)-I, IGF-II, and IGF binding protein (IGFBP)-3 in a population of obese children with biopsy-proven nonalcoholic fatty liver disease (NAFLD) with clinical, biochemical, and histological features. STUDY DESIGN: We conducted a cross-sectional study at the Hepatometabolic Unit of the Bambino Gesù Children's Hospital, Rome, Italy. Obese children (42 girls and 57 boys) underwent liver biopsy, anthropometry, biochemical assessment, and IGF system evaluation. Serum concentrations of IGF-I, IGF-II, and IGFBP-3 were measured. The liver biopsy features of each case were graded according to the NAFLD Activity Scoring system. The degrees of steatosis, inflammation, ballooning, and fibrosis were calculated. RESULTS: Nonalcoholic steatohepatitis was diagnosed in 14/99 obese subjects. Stepwise regression analysis revealed that IGF-I was the major predictor of ballooning (β = -0.463; P < .0001) and NAFLD activity score (β = -0.457; P < .0001), IGF-I/IGFBP-3 ratio was the major predictor of liver inflammation (β = -0.285; P = .005), and IGF-II was the major predictor of liver fibrosis (β = 0.343; P < .005). CONCLUSION: Circulating levels of IGF-I and IGF-II are associated with the histological stages of NAFLD and may represent novel markers of liver damage progression in obese children.
OBJECTIVE: To correlate circulating levels of insulin-like growth factor (IGF)-I, IGF-II, and IGF binding protein (IGFBP)-3 in a population of obesechildren with biopsy-proven nonalcoholic fatty liver disease (NAFLD) with clinical, biochemical, and histological features. STUDY DESIGN: We conducted a cross-sectional study at the Hepatometabolic Unit of the Bambino Gesù Children's Hospital, Rome, Italy. Obesechildren (42 girls and 57 boys) underwent liver biopsy, anthropometry, biochemical assessment, and IGF system evaluation. Serum concentrations of IGF-I, IGF-II, and IGFBP-3 were measured. The liver biopsy features of each case were graded according to the NAFLD Activity Scoring system. The degrees of steatosis, inflammation, ballooning, and fibrosis were calculated. RESULTS:Nonalcoholic steatohepatitis was diagnosed in 14/99 obese subjects. Stepwise regression analysis revealed that IGF-I was the major predictor of ballooning (β = -0.463; P < .0001) and NAFLD activity score (β = -0.457; P < .0001), IGF-I/IGFBP-3 ratio was the major predictor of liver inflammation (β = -0.285; P = .005), and IGF-II was the major predictor of liver fibrosis (β = 0.343; P < .005). CONCLUSION: Circulating levels of IGF-I and IGF-II are associated with the histological stages of NAFLD and may represent novel markers of liver damage progression in obesechildren.
Authors: Veeral Ajmera; Emily R Perito; Nathan M Bass; Norah A Terrault; Katherine P Yates; Ryan Gill; Rohit Loomba; Anna Mae Diehl; Bradley E Aouizerat Journal: Hepatology Date: 2016-10-12 Impact factor: 17.425
Authors: Andre Sarmento-Cabral; Mercedes Del Rio-Moreno; Mari C Vazquez-Borrego; Mariyah Mahmood; Elena Gutierrez-Casado; Natalie Pelke; Grace Guzman; Papasani V Subbaiah; Jose Cordoba-Chacon; Shoshana Yakar; Rhonda D Kineman Journal: J Endocrinol Date: 2021-01 Impact factor: 4.286
Authors: Sonja M Kessler; Stephan Laggai; Elien Van Wonterg; Katja Gemperlein; Rolf Müller; Johannes Haybaeck; Roosmarijn E Vandenbroucke; Manfred Ogris; Claude Libert; Alexandra K Kiemer Journal: Front Physiol Date: 2016-04-25 Impact factor: 4.566
Authors: Emily R Perito; Veeral Ajmera; Nathan M Bass; Philip Rosenthal; Joel E Lavine; Jeffrey B Schwimmer; Katherine P Yates; Anna Mae Diehl; Jean P Molleston; Karen F Murray; Ann Scheimann; Ryan Gill; David Glidden; Bradley Aouizerat Journal: Hepatol Commun Date: 2017-07-17